JPWO2020247392A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247392A5 JPWO2020247392A5 JP2021571993A JP2021571993A JPWO2020247392A5 JP WO2020247392 A5 JPWO2020247392 A5 JP WO2020247392A5 JP 2021571993 A JP2021571993 A JP 2021571993A JP 2021571993 A JP2021571993 A JP 2021571993A JP WO2020247392 A5 JPWO2020247392 A5 JP WO2020247392A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- genetically engineered
- cells
- express
- genetically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015446A JP2025081360A (ja) | 2019-06-04 | 2025-01-31 | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857167P | 2019-06-04 | 2019-06-04 | |
| US62/857,167 | 2019-06-04 | ||
| US201962943697P | 2019-12-04 | 2019-12-04 | |
| US62/943,697 | 2019-12-04 | ||
| PCT/US2020/035752 WO2020247392A1 (en) | 2019-06-04 | 2020-06-02 | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015446A Division JP2025081360A (ja) | 2019-06-04 | 2025-01-31 | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535429A JP2022535429A (ja) | 2022-08-08 |
| JP2022535429A5 JP2022535429A5 (https=) | 2023-06-09 |
| JPWO2020247392A5 true JPWO2020247392A5 (https=) | 2023-06-09 |
| JP7629414B2 JP7629414B2 (ja) | 2025-02-13 |
Family
ID=73652681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571993A Active JP7629414B2 (ja) | 2019-06-04 | 2020-06-02 | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
| JP2025015446A Pending JP2025081360A (ja) | 2019-06-04 | 2025-01-31 | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015446A Pending JP2025081360A (ja) | 2019-06-04 | 2025-01-31 | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220233593A1 (https=) |
| EP (1) | EP3980450A4 (https=) |
| JP (2) | JP7629414B2 (https=) |
| CN (1) | CN114174325A (https=) |
| AU (1) | AU2020288829A1 (https=) |
| CA (1) | CA3140393A1 (https=) |
| WO (1) | WO2020247392A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2021146147A1 (en) * | 2020-01-13 | 2021-07-22 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| WO2021252804A1 (en) | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| WO2022040577A1 (en) * | 2020-08-20 | 2022-02-24 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| JP2023552998A (ja) * | 2020-12-03 | 2023-12-20 | ンカルタ・インコーポレイテッド | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022150392A1 (en) * | 2021-01-05 | 2022-07-14 | City Of Hope | Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof |
| EP4305069A4 (en) * | 2021-03-08 | 2025-01-01 | University of Pittsburgh - of the Commonwealth System of Higher Education | MOLECULES THAT BIND TO CD66E POLYPEPTIDES |
| US20240197782A1 (en) * | 2021-04-20 | 2024-06-20 | Board Of Regents, The University Of Texas System | Methods and compositions for genetic modification and therapeutic use of immune cells |
| WO2022242701A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified gamma-delta t cells and uses thereof |
| WO2022242700A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified nk cells and uses thereof |
| AU2022301302A1 (en) * | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| CN117730094A (zh) * | 2021-07-16 | 2024-03-19 | 克莱格医学有限公司 | 用于肿瘤免疫学的组合物和方法 |
| EP4426319A1 (en) * | 2021-11-04 | 2024-09-11 | APHP (Assistance Publique - Hôpitaux de Paris) | Method for generating nk cells |
| TW202405165A (zh) * | 2022-04-14 | 2024-02-01 | 日商第一三共股份有限公司 | 編碼膜型細胞激素及tnf受體超家族分子之細胞內域的多核苷酸 |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| EP4558152A2 (en) * | 2022-07-22 | 2025-05-28 | Board of Regents, The University of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115948341B (zh) * | 2022-11-28 | 2025-05-16 | 上海恩凯细胞技术有限公司 | 敲低nkg2a基因的car-免疫细胞及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7868159B2 (en) * | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20120192298A1 (en) * | 2009-07-24 | 2012-07-26 | Sigma Aldrich Co. Llc | Method for genome editing |
| US9487800B2 (en) | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| AU2015259877B2 (en) * | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| CA2976089C (en) * | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| SG11201708516YA (en) * | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| ES2952064T3 (es) | 2015-12-16 | 2023-10-26 | Walter & Eliza Hall Inst Medical Res | Inhibición de la proteína SH2 inducida por citocinas en células NK |
| KR102438360B1 (ko) * | 2016-03-04 | 2022-08-31 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EP3519443A4 (en) * | 2016-09-30 | 2020-06-10 | Baylor College of Medicine | CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE |
| CN110267982B (zh) * | 2016-10-19 | 2024-02-23 | 斯克利普斯研究所 | 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途 |
| CA3041831A1 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
| US20180100016A1 (en) * | 2016-12-22 | 2018-04-12 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| JP2020503043A (ja) * | 2016-12-30 | 2020-01-30 | セルラリティ インコーポレイテッド | 遺伝子改変されたナチュラルキラー細胞 |
| KR102660336B1 (ko) * | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN108728459B (zh) * | 2017-04-24 | 2023-08-04 | 上海恒润达生生物科技股份有限公司 | 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途 |
| BR112020008478A2 (pt) * | 2017-11-01 | 2020-10-20 | Editas Medicine, Inc. | métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia |
| EP3749770B9 (en) * | 2018-02-09 | 2025-12-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Tethered interleukin-15 and interleukin-21 |
| MX2020011697A (es) | 2018-05-03 | 2020-12-10 | Univ Texas | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. |
| CN110724199B (zh) * | 2018-07-17 | 2023-12-05 | 成都盛世君联生物技术有限公司 | Nkg2d car-t细胞及其制备和应用 |
| WO2020113029A2 (en) * | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| EP3924467A1 (en) * | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| AU2020232691B2 (en) * | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CA3139346A1 (en) * | 2019-05-07 | 2020-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cell targeting bcma and use thereof |
| MX2022001255A (es) * | 2019-07-31 | 2022-05-10 | Nkarta Inc | Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales. |
| US20220389383A1 (en) * | 2019-11-27 | 2022-12-08 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of nk cells |
-
2020
- 2020-06-02 JP JP2021571993A patent/JP7629414B2/ja active Active
- 2020-06-02 CN CN202080053244.XA patent/CN114174325A/zh active Pending
- 2020-06-02 US US17/596,166 patent/US20220233593A1/en active Pending
- 2020-06-02 EP EP20818539.7A patent/EP3980450A4/en active Pending
- 2020-06-02 AU AU2020288829A patent/AU2020288829A1/en active Pending
- 2020-06-02 CA CA3140393A patent/CA3140393A1/en active Pending
- 2020-06-02 WO PCT/US2020/035752 patent/WO2020247392A1/en not_active Ceased
-
2025
- 2025-01-31 JP JP2025015446A patent/JP2025081360A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020247392A5 (https=) | ||
| Kloess et al. | CAR-expressing natural killer cells for cancer retargeting | |
| JP2022184852A5 (https=) | ||
| Figueroa et al. | Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy | |
| JP2021505131A5 (https=) | ||
| Ljunggren et al. | Prospects for the use of NK cells in immunotherapy of human cancer | |
| Leung | Infusions of allogeneic natural killer cells as cancer therapy | |
| Boussi et al. | Immunotherapy for the treatment of multiple myeloma | |
| JP2021519061A5 (https=) | ||
| JP2018532407A5 (https=) | ||
| IL270415B2 (en) | Materials and methods for engineering cells and uses thereof in immuno-oncology | |
| IL300729B2 (en) | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation | |
| Mehta et al. | Can we make a better match or mismatch with KIR genotyping? | |
| JPWO2019191495A5 (https=) | ||
| JPWO2019157454A5 (https=) | ||
| JPWO2021252804A5 (https=) | ||
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| JPWO2019215500A5 (https=) | ||
| JP2021505604A5 (https=) | ||
| Burga et al. | Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells | |
| de Witte et al. | Requirements for effective antitumor responses of TCR transduced T cells | |
| Hasan et al. | Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy | |
| JPWO2021071962A5 (https=) | ||
| Bonini et al. | Genome editing in engineered T cells for cancer immunotherapy | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells |